Illumina, Inc. (NASDAQ:ILMN) Receives Consensus Rating of “Hold” from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have earned an average recommendation of “Hold” from the nineteen brokerages that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $123.0556.

Several equities research analysts have recently commented on the company. Daiwa America lowered Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 12th. Piper Sandler cut their price objective on Illumina from $190.00 to $185.00 and set an “overweight” rating for the company in a research report on Thursday, May 15th. Robert W. Baird lifted their price objective on Illumina from $84.00 to $105.00 and gave the stock a “neutral” rating in a research report on Monday, July 28th. Stephens set a $110.00 price objective on Illumina and gave the stock an “overweight” rating in a research report on Monday, August 4th. Finally, Canaccord Genuity Group lifted their price objective on Illumina from $99.00 to $105.00 and gave the stock a “hold” rating in a research report on Friday, August 1st.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $98.18 on Tuesday. The business’s 50 day simple moving average is $99.68 and its 200-day simple moving average is $88.42. The firm has a market capitalization of $15.09 billion, a price-to-earnings ratio of 12.43, a price-to-earnings-growth ratio of 2.22 and a beta of 1.43. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. Illumina has a 12 month low of $68.70 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.02 by $0.17. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company’s quarterly revenue was down 4.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, equities analysts forecast that Illumina will post 4.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Illumina by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company’s stock worth $1,298,928,000 after purchasing an additional 558,243 shares during the last quarter. WCM Investment Management LLC raised its holdings in Illumina by 5.9% in the 2nd quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock valued at $419,585,000 after acquiring an additional 247,460 shares during the last quarter. Loomis Sayles & Co. L P raised its holdings in Illumina by 1.9% in the 2nd quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock valued at $403,158,000 after acquiring an additional 78,317 shares during the last quarter. Corvex Management LP raised its holdings in Illumina by 125.2% in the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock valued at $303,841,000 after acquiring an additional 2,129,449 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in Illumina by 55.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock valued at $313,290,000 after acquiring an additional 1,174,295 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.